Why plasma therapy to fight the pandemic is risky
Dear Balbir Singh Sooch,
Unfazed by the rumblings in the economy, Reliance Jio has been raking it in. Over the last couple of months, it has drawn attention — and funds — from the world’s top companies, scoring a list of firsts along the way. Our lead story takes a crystal-ball look if the company can some day also push India a few notches up in the world order.
TECH
Tech companies as geopolitical ambassadors
In a world where private tech companies are an intrinsic part of geopolitical moves, there is a position lying vacant to be India’s techno-nationalism vehicle to the world. At the company’s annual general meeting on July 15, Reliance Industries’ chairman Mukesh Ambani gave several hints about Jio’s global ambitions. Having just raised USD20 billion for Jio, can he use the financial heft, strategic partnerships, and influence to build an Indian tech giant capable of creating a global sphere of influence?
PHARMA
Why plasma therapy to fight the pandemic is risky
It’s a seemingly easy, affordable, and low-risk treatment being suggested for Covid-19 patients. In reality, plasma therapy remains an experimental intervention and has failed to scale up as a standard treatment. Anecdotal results have helped fuel hype about the therapy, highlighting the need for hard evidence backed by standard safety procedures.
TECH
Coaching institutes get ready to take on Byju’s, Unacademy
The viral outbreak has forced coaching institutes such as Aakash Educational Services, CL Educate, and FIITJEE to shutter their physical centres, and take students and teachers to mobile and Web platforms. But will the migration — from a physical-touch, high-value, and high-premium method to a low-touch digital-delivery model — be sustainable in the long run?
Regards,
ET Prime Team